Skip to main content
Premium Trial:

Request an Annual Quote

PPO MultiPlan Covering GenomeDx's Prostate Cancer Test

NEW YORK (GenomeWeb) – Prostate cancer diagnostics firm GenomeDx today announced it has signed a contract with MultiPlan for diagnostic laboratory testing.

As result of the deal, members of the preferred provider organization will have access to GenomeDx's Decipher Prostate Cancer Classifier, which measures a patient's biological risk of developing metastatic prostate cancer. MultiPlan has more than 500,000 providers in its network.

In June, GenomeDx and Prime Health Services inked a deal providing coverage for Decipher, and more than 190 million covered lives now have access to GenomeDx's test, the San Diego-based company said.

Decipher uses whole-genome analysis to profile RNA expression signatures to measure the aggressiveness of prostate cancer in patients who have had a prostatectomy. The test provides information that is distinct from PSA information and other clinical risk factors.